Three weeks after Roche’s Genentech unit walked away from an SHP2 inhibitor pact, Relay Therapeutics has confirmed that it won’t be pushing ahead with the asset solo.nnGenentech initially paid $75 million upfront in 2021 to license Relay’s SHP2 inhibitor, a molecule referred to at various times as RLY-1971, migoprotafib or GDC-1971. At the time, Genentech’s thinking was that migoprotafib could be paired with its KRAS G12C inhibitor GDC-6036.
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Roche’s Genentech has scuttled its SHP2 inhibitor pact, returning the rights to Relay Therapeutics after plowing more than $120 million into the alliance. The action is the latest in a series of terminations of SHP2 deals.
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Upcoming Investor Conferences
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024